focus -WSS

focus

author：hotspot 2025-09-27 22:18:25 - browse：78745

Two people in protective equipment work in a lab. — JUAN MABROMATA/AFP via Getty Images

Biosimilars are no longer a new and untested class of medicines. Today, they provide critical treatment options across multiple therapeutic areas. Since the Biologics Price Competition and Innovation Act of 2009 created a regulatory pathway for biosimilar medicine review in the U.S., 37 biosimilars have come to market offering the potential to increase patient choice and cost savings. And according to the 2023 analysis from IQVIA, biosimilars are expected to generate $181 billion in savings for the U.S. health care system over the next five years.

This progress is due, in part, to thoughtfully considered, scientifically robust regulatory standards, which have instilled confidence among health care providers and patients while protecting safety. As a former associate director of therapeutic biologics at the Food and Drug Administration, I had the privilege of helping create and lead implementation of the regulatory framework for biosimilars. The FDA took great care to apply appropriate scientific rigor to the development and approval standards. While I have since moved to Amgen, my goals have remained focused on biosimilar product quality and efficacy, patient safety, and prescriber confidence.

More than a decade later, collective efforts by biosimilar manufacturers and the FDA are paying off.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Pfizer plans to depart BIO

WSS

Supreme Court wrestles with OxyContin maker's bankruptcy deal

The surgeon had a dilemma only a Nazi medical text could resolve

Teach medical students about patients with intellectual disabilities

FDA needs staff influx to meet gene therapy needs, Marks says

FDA approves world's first CRISPR

Humana cuts profit projections as Medicare Advantage costs soar

hotspot

focus

focus

How to save PrEP access — and even expand it

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Test for long Covid? Researchers find new clue in blood samples

Drug repurposing or repositioning? The language matters

Spinal cord stimulation reduces pain in amputees, study finds

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

My yearlong odyssey to get my son’s ADHD medication covered

Continuity nursing helped my family in our darkest PICU moments

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

focus

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

AI generated plenty of interest at JPM but not a lot of trust

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

FDA needs staff influx to meet gene therapy needs, Marks says

AI generated plenty of interest at JPM but not a lot of trust

Medicare Advantage today, explained in one chart

explore

entertainment

explore

knowledge